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Abstract 
Alzheimer’s disease is characterized by progressive dementia, cortical atrophy with synaptic loss, and the accumulation of neurofibrillary tangles 
and senile plaques containing B-amyloid. The B-amyloid protein precursor @-APP), may normally be involved in cell adhesion related to synaptic 
maintenance. Loss of synapses correlates with dementia, suggesting that synaptic deficits may underlie the disease. Synapse stability may depend 
on the action of tissue transglutaminase (tTG), an enzyme capable of crosslinking large, multi-domain extracellular glycoproteins, that is active and 
present at synapses. We now show that B-APP is a substrate for tTG in vitro that results in dimers and multimers by silver staining and 
immunoblotting. This novel post-translational modification suggests further roles for /?-APP in synaptic function as well as in Alzheimer’s disease. 
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1. Introduction 
/?-APP, a 106110 kDa glycoprotein with three major 
isoforms, APPbV5, APPT5,, and APP7,,,, is encoded by a 
single gene [l-3]. The larger 751 and 770 isoforms con- 
tain the Kunitz protease inhibitor domain (KPI), lacking 
in the APP,,, isoform [3-S]. /S-APP undergoes extensive 
post-translational processing including glycosylation, 
sulfation, and proteolytic cleavage. These molecular 
changes have functional significance related to cell adhe- 
sion, regulation of neuronal growth, and protease inhibi- 
tion [6]. Although controversial, APP,,, and APP,,, are 
the predominant forms of the protein in the brain [7], 
whereas in the peripheral nervous system, all three are 
found equally. 
Tissue transglutaminase (EC 2.3.2.13; tTG) catalyzes 
the calcium-dependent intermolecular cross-linking of 
proteins via glutamine and lysine residues, both present 
in /LAPP. Cross-linking involves an acyl-transfer reac- 
tion where the y-carboxamide groups of peptide-bound 
glutamine residues act as acyl donors to the acyl ac- 
ceptors, primary amino groups of lysine or other 
compounds, forming either .+(y-glutamyl)lysine or 
(y-glutamyl)polyamine bonds. These covalent bonds are 
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resistant to proteolysis by chemical means, including 
SDS, urea, guanidine, and reducing compounds [8]. tTG 
is ubiquitous and serves many biological functions in- 
cluding the formation of fibrin in blood clotting [9], rigid 
cross-linking of proteins as in erythrocyte membranes 
[lo], in senile cataract formation in the optic lens [ll], 
and in the cornified envelope of human epidermal ker- 
atinocytes [ 121. 
Evidence strongly suggests that /3-APP functions as a 
cell adhesion molecule in the nervous system [13-l 81. A 
number of extracellular matrix (ECM) molecules uch as 
collagen, laminin, fibronectin, and thrombospondin act 
as substrates for tTG [19,20]. After cleavage by the secre- 
tase enzyme, /3-APP becomes an extracellular glycopro- 
tein and, therefore, might also be a natural substrate for 
tTG. In this study, we show that guinea pig liver tTG 
catalyzes the in vitro crosslinking of purified recombi- 
nant /SAPP770 into homodimers and multimers. 
2. Materials and methods 
Purified recombinantp-APP,,, from E. co/i, was a generous gift from 
Dr. B.D. Greenberg (Cephalon, Inc., West Chester, PA). Guinea pig 
liver tTG (Sigma, St. Louis, MO) was resuspended in 50 mM Tris-HCI 
buffer, pH 7.2, 0.9% NaCl at 1 pg/@. All procedures were carried out 
on ice or at 4°C. The reaction mixture consisted of 3 ,ug tTG, 60 ng 
B-APP,,o, 6 mM CaCl,, protease inhibitor ‘cocktail’ (lOOpg/ml soybean 
trypsin inhibitor, 5 mg/l leupeptin, 5 mg/l pepstatin, 135 KIU/ml aprot- 
inin), in 50 mM Tris-HCl, pH 7.2,0.9% NaCl, in a final reaction volume 
of 20 ~1. The reaction was allowed to proceed at 37°C for 1 h, and then 
stopped by the addition of 30 mM EDTA in Tris buffer, pH 7.2. The 
reaction mixture was diluted with SDS-containing sample buffer, boiled 
at 100°C for 5 min, and then subjected to SDS-PAGE on pre-cast 
412% Tris-Glycine gradient gels (Novex, San Diego, CA). Afterwards, 
the immobilized proteins were subjected to electrotransfer onto nitro- 
cellulose membranes overnight at 4”C, and blocked for one hour in 5% 
bovine serum albumin (Sigma) in PBS/Tween-20 to eliminate nonspe- 
cific binding. Enhanced chemiluminescence Western blotting (ECL, 
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Amersham, Arlington Heights, IL; DuPont, Boston, MA) was per- 
formed using monoclonal anti-,&APP primary antibody (clone 22Cll; 
Boehringer Mannheim, Indianapolis, IN) and goat, anti-mouse second- 
ary antibody linked to horseradish peroxidase (Amersham). Other 
membranes were immunoblotted with anti-GID polyclonal antibody 
specific for residues 175-186 of B-APP (generous gift of Dr. Saitoh, 
UCSD, La Jolla, CA). Membranes were developed as instructed by 
manufacturers and then exposed to radiographic film (XAR-OMAT, 
Kodak, Rochester, NY). 
For the next experiments, eight reaction mixtures, representing the 
eight time points, in duplicate, were prepared as described in Fig. 1, and 
incubated in a 37°C dry bath for appropriate amounts of time. They 
were subsequently placed at 4”C, and the reaction halted by the addi- 
tion of 5 mM EDTA in Tris, pH 7.2. After the final tube completed 
incubation, SDS-containing sample buffer was added to each mixture. 
The mixtures were boiled at 100°C for 5 min, and separated by SDS- 
PAGE on a 412% pre-cast Tris-Glycine gel. Gels were stained with 
silver [21] and analysed by laser densitometry (Pharmacia Ultroscan). 
Each gel was scanned three times, and error bars were derived from this 
data. Band densities were plotted as a function of time using SigmaPlot 
(Jandel, San Rafael, CA). 
3. Results 
In our effort to further characterize the function and 
interactions of /?-APP which might be relevant to Alz- 
heimer’s disease pathogenesis, we found that tTG is able 
to catalyze cross-linking ofj&APP,,, in vitro. In the pres- 
ence of /3-APP, tTG and calcium, we found both a 
dimeric form, approximately 212 kDa, and higher kDa 
/3-APP multimers that remained at or close to the top of 
the gel after SDS-PAGE (Fig. 1, lane 4), in addition to 
the p-APP monomer (106 kDa). The 212 kDa band, and 
the p-APP multimers (-424 kDa), were absent when ei- 
ther p-APP or tTG were incubated with calcium alone, 
but not combined (Fig. 1, lanes l-3). Similar results were 
obtained for purified recombinant human /?-APP,,, (not 
shown). The monomeric p-APP,,,, dimeric /?-APP, and 
the multimeric j?-APP bands were recognized by mono- 
clonal antibody against the N-terminal region of P-APP 
(clone 22Cll). A polyclonal anti-GID antibody, specific 
for residues 175-186 of /3-APP [14], also recognized pre- 
cisely the same pattern of bands as the 22Cll antibody 
(Fig. 1, lanes 5-7). We included protease inhibitors in the 
reaction so that the disappearance of the monomeric 
j&APP band at 106 kDa could not be attributed to pro- 
tease action. 
Having obtained these results, we determined if a sub- 
strate:product relationship of monomers to insoluble 
/?-APP dimers and multimers existed by incubating 
B-APP,,,, tTG and calcium for various times from 
O-120 min (Fig. 2a, lanes 2-10). A monomeric 106 kDa 
band was clearly observed (lane 2) which decreases in 
intensity with time (lanes 3 through 10) as higher J4, 
forms increase. No bands at 212 kDa, or at the level of 
multimers, were noted at zero time, while progressive 
increase in the intensity of these protein bands with time 
was observed (lanes 2 through 10). In order to better 
quantify the reaction between 0 and 10 min, similar ex- 
periments were carried out for time points from 2 to 
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Fig. 1. Tissue transglutaminase cross-linking of B-APP,70 detected by 
immunoblotting. Lanes 14 immunoblotted using 22C11 monoclonal 
antibody and lanes 5-7, using anti-GID polyclonal antibody as in 
section 2. Lane 1 shows tTG only; lane 2, /?-APP,,, only; lane 3, tTG 
with CaCl,; lane 4, /3-APP,,,, tTG and CaCl,; lane 5, tTG only, lane 
6, B-APP,,, only; lane 7, B-APP,,,, tTG and CaCI,. Arrows indicate 
106 kDa monomer band, 212 kDa dimer band, and 424 kDa (or larger) 
multimer band, respectively. 
8 minutes, as shown in the inserts in Fig. 2b-d. In these 
experiments, we found dimers and multimers as early as 
2 min of incubation. By 40 min the multimeric band 
appeared to be maximal, with a concomitant decrease in 
the p-APP monomeric (106 kDa) band. Densitometric 
analysis of the three bands showed that both insoluble 
dimer and high M, multimers are inversely related to the 
loss of the soluble monomeric /LAPP (Fig. 2b-d). The 
loss of monomer and increase in dimers of j?-APP, 
catalyzed by tTG, is essentially complete after 40 min 
incubation. At 40 min, 27 + 1% (S.E.M.) of monomer 
remained, while 33 + 1% and 41 f 2% of dimers and 
multimers, respectively, had been produced. Confirming 
the qualitative findings, the 106 kDa j?-APP monomer 
diminishes as a function of time, while dimeric and mul- 
timeric forms increase, forming an inverse relationship 
between substrate and product. 
4. Discussion 
Increased protein cross-linking catalyzed by tTG, ac- 
companying the transition of a cell from a mitotic to 
post-mitotic state [22,23], has prompted a detailed exam- 
ination of the role of tTG in the nervous system. tTG 
activity is present in human [24] as well as in rat brain 
[25], rat brain synaptosomal preparations [25] and 
peripheral nerves [26]. More pertinent to p-APP, the re- 
cent identification of specific glutamine and lysine resi- 
dues in j?-amyloid peptide (residues l-28), which partici- 
pate in tTG-catalyzed homopolymerization and hetero- 
polymerization with a,-macroglobulin receptor [27,28], 
suggests possible sites for cross-linking in the precursor. 
The association of p-APP with the ECM has been dem- 
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Fig. 2. Relationship between monomeric B-APP,,,, dimeric and multimeric p-APP,,, over time. (a) SDS-PAGE demonstrates the amount of product 
and substrate over the time course. Lane I, molecular weight markers; lane 2, time point 0; lane 3, IO min; lane 4, 20 min; lane 5, 30 min; lane 6, 
40 min; lane 7, 50 min; lane 8,60 min; lane 9,90 min; lane IO, 120 min. (b-d) shows densitometric analysis of the gel in 2a. Open circles are monomers, 
closed circles, dimers, and closed triangles, multimers. Values are expressed as relative band density as % of control, where 100% represents the band 
density of 60 ng of standard B-APP,,,. Inserts show the course of the reaction between 0 and 10 min. 
on&rated by electron microscopy [ 151 and accumulated 
evidence supports a role for /I-APP in cell adhesion. 
Anti-/I-APP antibodies prevent the adhesion of cultured 
cells to cell-substrata as well as neuron-neuron and 
neuron-glial contact in culture [15,16]. Our finding that 
B-APP,,, is cross-linked by tTG, reinforces the concept 
that the secreted protein is, or becomes, an essential 
component of the ECM, stabilizing cellular attachments 
and preventing further neuritic growth. Cross-linked 
/3-APP, either homo- or hetero-forms, may act as a sup- 
porting infra-structure, stabilizing synaptic sites. Fur- 
thermore, cross-linking of /I-APP, as a normal biochem- 
ical event for cell growth and survival, may alter, retard, 
or even preclude proteolytic cleavage of the precusor 
molecule and prevent generation of /3-amyloid peptide. 
The secreted forms of /I-APP are identical to protease 
nexin II (PNII), a potent Kunitz-type inhibitor of several 
serine proteases including trypsin, chymotrypsin and 
both factors IXa and XIa of the coagulation cascade 
[29,30]. Since, /I-APP undergoes fast anterograde trans- 
port in the axon to presynaptic sites [3 11, and is localized 
to both central and peripheral synapses [32,33], it is 
highly possible that the protein also becomes an essential 
component in the synaptic cleft ECM. Loss of synapses 
154 G.J. Ho et al. IFEBS Letters 349 (1994) 151-154 
correlates best with dementia [34], making defects in 
synaptic maintenance a strong candidate underlying 
Alzheimer’s disease. Stable, homo- or hetero-cross- 
linked ,&APP, from pre-synaptic to post-synaptic mem- 
brane or from synapse to ECM (or its equivalent in the 
brain) would also serve to stabilize potent serine protease 
inhibitor (i.e. PNII) activity at synaptic sites. In this 
regard, four other serine protease inhibitors, of some 50 
known macromolecules identified, have so far been lo- 
calized to vertebrate synapses. The first to be discovered 
was protease nexin I (PNI), a serpin related to PNII, but, 
in addition, a,-antichymotrypsin, and the synapse-or- 
ganizing, acetylcholine receptor-aggregating molecule, 
agrin, are also synapse-localized [35-371. The presence of 
tTG activity at the peripheral, cholinergic, nicotinic, neu- 
romuscular synapse [38] argues for its role at central 
synapses, as well. With both enzyme (tTG) and sub- 
strates, such as laminin, thrombospondin, fibronectin 
and, now, /I-APP, significant implications for the in- 
volvement of tTG in Alzheimer’s disease, where muta- 
tion or abnormal function of the enzyme may result in 
synapse loss, are possible. 
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